Back

What does Serum Glycosylated Apolipoprotein J mean in a heart attack?-----Correlation of serum glycosylated apolipoprotein J with acute myocardial infarction

yao, r.; Ren, M.; Dong, H.; Wang, H.; Jia, W.; Ding, X.; Fu, K.; Wang, A.; Zhu, X.; gong, l.; Zhong, L.

2023-06-20 cardiovascular medicine
10.1101/2023.06.19.23291631
Show abstract

BackgroundThere are few myocardial damage markers that could be used to diagnose acute myocardial infarction(AMI) or assess its severity, especially glycosylated apolipoprotein J(ApoJ-Glyc) has demonstrated superiority in cardiomyocytes and animal STEMI models in the early stages of myocardial ischemia(MI). We aimed to excavate the potential role of ApoJ-Glyc as a protein marker in the pathogenesis of AMI in humans and its added value in the evolution of the disease. Methods and ResultsELISA was used to determine the serum concentration of ApoJ-Glyc in 163 patients enrolled by the criteria. Statistical analysis could used to discuss the relationship between ApoJ-Glyc and AMI. Compared to control groups, serum ApoJ-Glyc levels decreased by 36% and 37% in early AMI patients and AMI patients, respectively (P<0.0001), showing a higher discriminant value for early diagnosis and diagnosis of AMI [area under the curve (AUC) : 0.871 and 0.886, P< 0.0001]. For the first time, we demonstrated that ApoJ-Glyc was not statistically significant in the comparative difference between NSTEMI and STEMI groups (P> 0.05). Patients with gradually declining ApoJ-Glyc had a higher Grace Risk Scores. Subsequent studies have also demonstrated that more MACCE did occur with a 6-month follow-up(P<0.05). ConclusionsApoJ-Glyc which serve as an alarm bell for the detection of early ischaemia, may be a new biomarker for AMI. ApoJ-Glyc can assess the severity of myocardial infarction. The continuous decrease of serum ApoJ-Glyc suggests an increase in the risk of post-AMI ischaemia and the onset of unpredictable MACCE. Graphic abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=110 SRC="FIGDIR/small/23291631v1_ufig1.gif" ALT="Figure 1"> View larger version (41K): org.highwire.dtl.DTLVardef@1d3b996org.highwire.dtl.DTLVardef@13d4482org.highwire.dtl.DTLVardef@15cf203org.highwire.dtl.DTLVardef@114de20_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Frontiers in Cardiovascular Medicine
based on 33 papers
Top 0.1%
22.4%
2
BMC Cardiovascular Disorders
based on 11 papers
Top 0.1%
9.3%
3
Journal of the American Heart Association
based on 92 papers
Top 3%
9.3%
4
Journal of Clinical Medicine
based on 77 papers
Top 2%
5.9%
5
The American Journal of Cardiology
based on 15 papers
Top 2%
3.3%
50% of probability mass above
6
Atherosclerosis
based on 16 papers
Top 0.9%
3.1%
7
International Journal of Cardiology
based on 13 papers
Top 0.9%
3.1%
8
PLOS ONE
based on 1737 papers
Top 75%
3.1%
9
European Heart Journal
based on 14 papers
Top 1%
3.1%
10
Scientific Reports
based on 701 papers
Top 56%
2.7%
11
Open Heart
based on 18 papers
Top 2%
2.7%
12
Biomedicines
based on 21 papers
Top 0.5%
2.7%
13
BMJ Open
based on 553 papers
Top 33%
2.6%
14
Circulation: Genomic and Precision Medicine
based on 30 papers
Top 3%
2.5%
15
Heart Rhythm
based on 16 papers
Top 2%
1.8%
16
Healthcare
based on 14 papers
Top 1%
1.5%
17
European Journal of Preventive Cardiology
based on 12 papers
Top 1%
1.3%
18
Frontiers in Neurology
based on 74 papers
Top 10%
0.9%
19
Medicine
based on 29 papers
Top 7%
0.9%
20
Arteriosclerosis, Thrombosis, and Vascular Biology
based on 11 papers
Top 2%
0.9%
21
Hypertension
based on 20 papers
Top 3%
0.9%
22
Journal of Stroke and Cerebrovascular Diseases
based on 10 papers
Top 1%
0.9%
23
Journal of Thrombosis and Haemostasis
based on 10 papers
Top 2%
0.7%